Anne O’Hagan

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Yohann Loriot, Andrea Necchi, Se Hoon Park et al. · New England Journal of Medicine · 2019 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +15

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma

Paolo A. Ascierto, David R. Minor, Antoni Ribas et al. · Journal of Clinical Oncology · 2013 · 427 citations

Medicine, Oncology, Pharmacology +16

Correlation of <i>BRAF</i> Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials

Ademi Santiago-Walker, Robert Gagnon, Jolly Mazumdar et al. · Clinical Cancer Research · 2015 · 201 citations

Medicine, Molecular Genetics, Oncology +17

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park et al. · The Lancet Oncology · 2022 · 169 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and <i>FGFR</i> alterations (FGFRalt).

Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park et al. · Journal of Clinical Oncology · 2018 · 73 citations

Medicine, Oncology, Pharmacology +15